OGXI 2.13 Oncogenex Pharmaceuticals Inc $OGXI Hit a 52 week

OGXI 2.13 Oncogenex Pharmaceuticals Inc $OGXI Hit a 52 week low of 2.08 Closing the day 11/10/14 at 2.13 -0.05 -2.29% With a day low of 2.08 and a total volume of 83,084.

OGXI Recent Posts: http://investorshangout.com/Oncogenex-Pharmac...GXI-54968/

OGXI Oncogenex Pharmaceuticals Inc Recent Headline News

Isis Pharmaceuticals Inc. Strikes Out on Its Own
Brian Orelli, The Motley Fool - Motley Fool - Fri Nov 07, 1:30PM CST
Until now, all of Isis Pharmaceuticals ' late-stage drugs involved partnerships with other companies. Kynamro, its only drug on the market, is sold by Sanofi , and phase 3 drug candidates ISIS-TTR, ISIS-SMN, and custirsen are respectively being...
BIIB: 327.87 (+7.12), ALNY: 99.18 (+3.34), ISIS: 47.23 (+2.64), OGXI: 2.13 (-0.05), TEVA: 58.04 (+0.34), RGLS: 20.91 (-1.17), GSK: 45.16 (+0.25), SNY: 46.19 (+0.50)

Biotech Watchlist Update: Small-Cap Biotechs Struggle, But Investors Remain Enchanted By Big Pharma's Returns
Life Sciences Report - Seeking Alpha - Fri Nov 07, 8:16AM CST
When the biotechnology market hit a speed bump in early 2014, every stock in the sector was jolted. Large-cap biotech and big pharma have largely recovered, but small- and micro-cap companies haven't yet entirely recouped the losses. The performance...
CERS: 4.03 (+0.02), PCYC: 133.98 (+0.49), CLDX: 14.81 (+1.39), INCY: 70.96 (+1.64), BIND: 9.64 (+0.42), CELG: 108.01 (+1.56), OMER: 17.49 (+0.12), VSTM: 9.08 (+0.05), GILD: 107.02 (+0.57), OGXI: 2.13 (-0.05), ANTH: 1.84 (unch), NVAX: 5.21 (+0.26)

OncoGenex Pharmaceuticals' (OGXI) CEO Scott Cormack on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 02, 3:04AM CST

OGXI: 2.13 (-0.05)

More on OncoGenex Pharmaceuticals Q3 results
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 1:32PM CDT

OGXI: 2.13 (-0.05)

OncoGenex Pharmaceuticals beats by $0.14, beats on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 3:34PM CDT

OGXI: 2.13 (-0.05)

OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Third Quarter 2014
CNW Group - Thu Oct 30, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) today provided a summary of clinical developments and announced third quarter 2014 financial results.
OGXI: 2.13 (-0.05), TEVA: 58.04 (+0.34)

Some Of Soros' Stocks Surged Today, While Others Soured
at The Street - Wed Oct 29, 3:31PM CDT
OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI), MCG Capital Corp (NASDAQ:MCGC) and Doral Financial Corp. (NYSE RL) made noteworthy gains on the market this Wednesday. In the red today are Cal Dive In...
OGXI: 2.13 (-0.05), MCGC: 3.66 (unch), INVN: 14.95 (-0.25), DRL: 5.13 (-0.37), ARCP: 8.50 (-0.29)

OncoGenex reports on October 30
Seeking Alpha - at Seeking Alpha - Thu Oct 16, 9:27AM CDT

OGXI: 2.13 (-0.05)

OncoGenex to Report Financial Results for Third Quarter 2014 on October 30, 2014
PR Newswire - Thu Oct 16, 5:30AM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Company's third quarter 2014 financial results will be released on Thursday, October 30, 2014, and that the Company will host a conference call and live webcast at 4:30 p.m. ET that afternoon. Management will provide an overview of the company's financial results, development programs and a general business update.
OGXI: 2.13 (-0.05)

OncoGenex's Phase III Prostate Cancer Study Fully Enrolled - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Sep 18, 4:11PM CDT
OncoGenex Pharmaceuticals, Inc. (OGXI) has finished enrolling patients in a phase III study (AFFINITY) on custirsen for metastatic castrate-resistant prostate cancer.
LCI: 51.81 (+1.64), ENDP: 68.87 (-0.09), OGXI: 2.13 (-0.05), TEVA: 58.04 (+0.34)

5 Stocks Under $10 to Trade for Breakouts
at The Street - Thu Sep 18, 6:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.
NLST: 0.74 (-0.02), ANY: 8.53 (-0.03), OGXI: 2.13 (-0.05), GLYC: 7.99 (+0.08)

OncoGenex Announces Completion of Patient Enrollment in the Phase 3 AFFINITY Trial of Custirsen in Combination with Cabazitaxel/Prednisone as Second-line Chemotherapy in Men with Metastatic Castrate-Resistant Prostate Cancer
PR Newswire - Tue Sep 16, 5:30AM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that patient enrollment has been completed in the Phase 3 AFFINITY trial.
OGXI: 2.13 (-0.05), TEVA: 58.04 (+0.34)

4 Under-$10 Biotech Stocks in Breakout Territory
at The Street - Wed Aug 27, 6:00AM CDT
These biotech stocks trading for less than $10 a share are within range of triggering breakout trades.
OGXI: 2.13 (-0.05), ARTX: 2.93 (+0.01), CYTR: 2.85 (-0.02), CNCE: 13.37 (+0.27)

OncoGenex's Custirsen Passes First Interim Futility Analysis - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:40PM CDT
OncoGenex Pharmaceuticals, Inc. (OGXI) announced that the IDMC has recommended the continuation of the phase III ENSPIRIT study on custirsen for lung cancer.
ENDP: 68.87 (-0.09), OGXI: 2.13 (-0.05), UTHR: 125.17 (+0.96), TEVA: 58.04 (+0.34)

OncoGenex Announces Update on Phase 3 ENSPIRIT Trial Evaluating Custirsen in Advanced Non-Small Cell Lung Cancer
PR Newswire - Thu Aug 21, 3:01PM CDT
OncoGenex Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that the Phase 3 ENSPIRIT trial, evaluating custirsen in the treatment of non-small cell lung cancer (NSCLC), is continuing as planned per the recommendation of the Independent Data Monitoring Committee (IDMC) based upon completion of the first interim futility analysis.
OGXI: 2.13 (-0.05), TEVA: 58.04 (+0.34)

OncoGenex Q2 Loss Narrower than Expected, Revenues Down Y/Y - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 08, 3:00PM CDT
OncoGenex Pharmaceuticals, Inc. (OGXI) reported a loss of 47 cents per share, narrower than the the Zacks Consensus Estimate of a loss of 49 cents.
AGN: 195.24 (-0.76), OGXI: 2.13 (-0.05), AZN: 73.21 (+0.33), TEVA: 58.04 (+0.34)